Duxil

Servier is a leading independent international pharmaceutical company governed by a non-profit foundation, headquartered in Suresnes, France. The company is well-known for its extensive portfolio in cardiovascular diseases, oncology, and neurosciences, including the commercialization of Duxil (almitrine + raubasine) for cerebrovascular disorders. Servier operates in over 150 countries and reinvests a significant portion of its revenue into research and development, particularly focusing on hard-to-treat cancers and chronic diseases. The company has significantly expanded its oncology presence through strategic acquisitions, such as Shire's oncology branch and Agios Pharmaceuticals' oncology business. Servier is committed to therapeutic innovation and maintains numerous global partnerships with academic and industrial leaders.